In addition to supporting a role for AR in melanoma progression, our results are consistent with previous findings showing that genetic or pharmacological manipulation of AR limits tumorigenesis, triggers senescence [13] and improves the response to B-RAF/MEK inhibitors [15] in preclinical and clinical melanoma models. The gene discussed is BRAF; the disease is melanoma.